Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system. GABA type A receptors (GABA A Rs) are severely affected in Alzheimer's disease (AD). However, the distribution and subunit composition of GABA A Rs in the AD brain are not well understood. This is the first comprehensive study to show brain region-and cell layer-specific alterations in the expression of the GABA A R subunits a1-3, a5, b1-3 and c2 in the human AD hippocampus, entorhinal cortex and superior temporal gyrus. In late-stage AD tissue samples using immunohistochemistry we found significant alteration of all investigated GABA A Rs subunits except for a3 and b1 that were well preserved. The most prominent changes include an increase in GABA A R a1 expression associated with AD in all layers of the CA3 region, in the stratum (str.) granulare and hilus of the dentate gyrus.
Gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the central nervous system (Docherty and Bradford 1986) , has a critical role in regulating neuronal excitability and information processing in the brain. Altered GABA-mediated signalling plays a key role in a number of pathological conditions affecting the nervous system, including Alzheimer's disease (AD) (Shiah and Yatham 1998; Fritschy 2008; Rudolph and Mohler 2014; Schousboe et al. 2014; Solas et al. 2015; Li et al. 2016) . AD is the most common form of neurodegenerative dementia (World Alzheimer's Report 2015) . In AD, the loss of memory and cognitive function is underpinned by widespread death of neurons in the hippocampus and cerebral cortex (Braak and Braak 1991) . Previous studies suggest that, while GABAergic cells are relatively resistant to AD pathology compared to cholinergic and glutamatergic systems (Reinikainen et al. 1988 ) the subunit composition of GABA type A receptors (GABA A Rs) is severely affected in the hippocampus of AD patients (Rissman et al. , 2007 Rissman and Mobley 2011; Limon et al. 2012) . GABA A Rs are pentameric complexes formed by co-assembly from at least 20 different subunit types, a1-6, b1-4, c1-3, q1-3, d, e, p and h, that are grouped according to the degree of sequence identity (Olsen and Tobin 1990; Mohler et al. 1996; Barnard et al. 1998; Bonnert et al. 1999) . The particular combination of subunits determines the receptors`cellular localization and pharmacological properties (Olsen and Sieghart 2009) . What remains controversial is how the subunits are affected in AD and which subunits exhibit most change. GABA A R subunit expression shows a remarkable complexity within the human and rodent brain (Sieghart et al. 1999; Loup et al. 2000) and this has to be taken into consideration when examining any disease-related changes. Hence, to provide a complete assessment of the GABA A Rs expression in AD the detailed spatial distribution of the expression also has to be examined in the AD brain compared to age-matched healthy controls.
In this study, we show alterations in the expression of GABA A R a1, a2, a5, b2, b3 and c2 subunits and preservation of the a3 and b1 subunits in the human AD hippocampus, subiculum, entorhinal cortex and superior temporal gyrus (STG) compared to healthy controls. We also show that these changes are complex, region-and layerspecific, then we propose that compensatory alterations of different GABA A R subunits might occur in AD.
Methods

Human brain tissue preparation
Research was carried out at the University of Auckland, Centre for Brain Research, Neuroanatomy Laboratory and was not preregistered. Donated post-mortem human brain tissue was obtained from the Neurological Foundation of New Zealand Douglas Human Brain Bank. The tissue was acquired through a donation program and the procedures were approved by the University of Auckland Human Participant's Ethics Committee (Approval number: 011654). Processing of tissue followed the procedure described previously (Waldvogel et al. 2006) . The right hemisphere of the brain was fixed by perfusion with 15% formalin, cut into anatomical blocks, cryoprotected with sucrose solutions and frozen at À80°C. Six control (Table 1) and six AD cases (Table 2) , with an average age of 81 years and maximum post-mortem time of 33 h were immunostained for GABA A R subunits a1-3, a5, b1-3 and c2. Control brains were selected from the Human Brain Bank and matched with the AD cases for age, sex and post-mortem delay. Based on power calculations on our previous studies it was assumed that a sample size of n = 5 per group would be necessary and sufficient to provide meaningful results to achieve 90% power and a significance level of 5%. However, additional cases were included to account for potential problems such as tissue damage.
Neuropathological analysis of human tissue
All control cases had no history of neurological disease abnormalities, whereas all of the Alzheimer's cases had clinical dementia. Standard sections, including the middle frontal-, middle temporal-, cingulate gyrus, hippocampus, caudate nucleus, substantia nigra, locus coeruleus, cerebellum, were examined from both control and AD cases by a neuropathologist. The neuritic plaque density in the AD cases was classified into sparse, moderate or frequent according to the criteria from the Consortium to Establish a Registry for Alzheimer's disease (Mirra et al. 1991) . Only those cases that were Consortium to Establish a Registry for Alzheimer's disease definite or probable AD were included in the study. The distribution and density of tau pathology was assessed immunohistochemically. The control cases did not show evidence of AD or another primary neurodegenerative disorder.
Immunohistochemistry
Coronal sections (60 lm) of the hippocampus, entorhinal cortex and STG were cut on a freezing microtome, and stored at 4°C in phosphate-buffered saline (PBS) containing 0.1% sodium azide. Free-floating 3,3 0 -diaminobenzidine (DAB)-peroxidase and fluorescent immunohistochemistry were utilized for visualization of GABA A R a1-3, a5, b1-3 and c2 subunits using a method published previously (Waldvogel et al. 2006; Lowe et al. 2015) . All antibodies dilutions were optimized. Specificity of the primary antibodies has been tested using western blotting ( Fig. 1 ) and reported previously (Ewert et al. 1990; Benke et al. 1991a,b; Gao et al. 1993; Marksitzer et al. 1993; Fritschy and Mohler 1995; Waldvogel et al. 1999; Loup et al. 2000; Schwirtlich et al. 2011; Kelley et al. 2013; Mueller et al. 2014) . The omission of the primary antibodies resulted in complete absence of immunoreactivity. Antibodies against GABA A R subunits and NeuN were diluted in 1% normal goat or donkey serum, and 0.04% methiolate in PBS (immunobuffer). Primary antibodies and dilutions are described in Table 3 .
DAB-peroxidase immunohistochemistry
Sections were incubated in citric acid buffer (pH 6.8) overnight at 4°C, followed by antigen retrieval conducted in a microwave oven on high power for 30 s (3 9 10 s, separated by 2 s), 30 min incubation at 23°C room temperature (RT). Sections were washed in PBS, 0.2% Triton X-100 (PBST) before blocking with a solution of 50% methanol and 1% H 2 O 2 for 20 min, followed by 3 9 10 min washes in PBST and incubated for 72 h in each primary antibody for GABA A R subunits at 4°C (Table 3) in immunobuffer. The sections were then washed in PBST before incubation for 24 h with the biotinylated secondary antibodies diluted at 1 : 2000 in immunobuffer. The sections were then washed in PBST before incubation with ExtrAvidin (1 : 1000, E2886; Sigma, St. Louis, MO, USA) in immunobuffer for 4 h, followed by 3 9 10 min washes in PBST before development in 0.05% DAB and 0.01% H 2 O 2 and 0.1 M phosphate with 0.04% nickel ammonium sulphate for 20 min. The b1 and b2 GABA A receptor subunits were stained using N-Histofine Simple Stain Max PO (414142F; Nichirei Biosciences Inc., Tokyo, Japan), following the manufacturer's instructions. Sections were washed in PBST and mounted onto glass slides, dried, dehydrated through a graded series of ethanol and cleared in xylene. The slides were coverslipped with DPX mountant (1019790500; Merck, Whitehouse Station, NJ, USA). The sections were imaged on either a Leica (Wetzlar, Germany) DMRB light microscope or a Leica MZ6 dissecting microscope. 
Fluorescent immunohistochemistry
Sections were incubated in PBST overnight at 4°C, followed by 3 9 10 min washes in PBST and incubated for 72 h in each primary antibody for GABA A R subunits and NeuN at 4°C (Table 3) to allow localization of neurons and distinction of regional layers. Following 3 9 10 min washes in PBST, the sections were incubated at 23°C RT for 24 h in secondary antibodies goat anti-rabbit Alexa , on all sections used for GABA A R density measurements. Adobe Photoshop CC 2014 (Adobe Systems Software, San Jose, CA, USA) was used to prepare the figures. The experimenter was blinded to the experimental groupings to eliminate any bias during the experiment, including image acquisition and analysis. Two hippocampal and two STG sections from each case were randomized, by a person not involved in the study, and numbered form 1 to 24.
Western blotting
Human cortical tissue samples were homogenized in a buffer containing 0.5 M Tris, 100 mM EDTA, 4% sodium dodecyl sulphate, pH 6.8 and protein extracts prepared using 0.5 mm glass beads (Mo-Bio Laboratories, Solano Beach, CA, USA) and a Mini Bullet Blender Tissue Homogeniser (Next Advance, Inc, New York, USA) at speed 8 for 8 min. The homogenates were incubated for 1 h on ice, then centrifuged at 10621 g for 10 min, the supernatant collected and stored at À20°C. The protein concentration of the samples was measured using detergent-compatible protein assay (DC Protein assay, 500-0116; Bio-Rad, Hercules, CA, USA), following the manufacturer's instructions. Twenty lg of each protein extract was run on a gradient -polyacrylamide electrophoresis gel (NU PAGE 4-12% BT 1.5, NP0336BOX; Life Technologies, Carlsbad, CA, USA) and then blotted. Proteins were separated in XCell SureLock Mini-Cell system (Invitrogen, Scoresby, Vic., Australia) and transferred onto nitrocellulose membranes using XCell Blot Module (Invitrogen). Two molecular weight ladders, Molecular weight or Magic mark (Life Technologies), were also loaded in gels as verification of labelled band size. Membranes were blocked with Odyssey blocking buffer (LI-COR Biosciences, Lincoln, Nebraska, USA) at room temperature for 30 min, followed by incubation with the primary antibodies (Table 3) , at 4°C overnight. The following day membranes were washed 3 9 10 min in Tris-buffered saline pH 7.6, 0.1% Tween and incubated with an appropriate IRDye (1 : 10 000, goat anti-rabbit IRDye â 680RD, 926-68071, RRID:AB_10956166; goat anti-mouse 
Statistical analysis
To examine the differences between groups, an unpaired MannWhitney test was used, as the data did not meet the assumptions (homogeneity of variance and normality) of parametric tests. Correlation analysis was performed using a Spearman's test. Data in all experiments were expressed as mean AE SEM. All statistical analyses were conducted using Prism (version 6; GraphPad Software Inc., San Diego, CA, USA) with a value of p < 0.05 considered significant.
Results
Expression of GABA A R a1-3 and a5 subunits in the human hippocampus, subiculum, entorhinal cortex and superior temporal gyrus A significant decrease in GABA A R a1 subunit expression was detected in AD compared to control cases in the str. (Fig. 3b 1 ; p = 0.004) and STG (Fig. 3b 7 ; p = 0.022) in AD cases.
There was no significant change in GABA A R a3 subunit protein expression in AD compared to control cases in any of the brain regions examined (Fig. 2c 1 ,c 2 ,g 1 ,g 2 and 3c ). For the subiculum and STG there was a trend towards a decrease in GABA A R a3 expression approaching, although not reaching, significance for AD cases (Fig. 3c 5 ,c 7 ) .
In AD there was a significant increase in GABA A R a5 subunit expression in the str. pyramidale, str. oriens of the CA1 region (Figs 2d 1 ,h 1 and 3d 1 ; p = 0.004), subiculum (Figs 2d 1 ,l 1 and 3d 5 ; p < 0.05) and decrease in the STG (Fig. 3d 7 ; p = 0.036).
Expression of GABA A R b1-3 subunits in the human hippocampus, subiculum, entorhinal cortex and superior temporal gyrus The GABA A R b1 subunit was well preserved in AD. We did not detect significant change in GABA A R b1 subunit protein expression in AD compared to control cases in any of the brain regions examined (Figs 5a 1 ,a 2 ,e 1 ,e 2 and 6a).
A significant increase in GABA A R b2 subunit expression was detected in AD compared to control cases in the str. oriens (p = 0.016) and str. radiatum (p = 0.016) of the CA2 region (Figs 5b 1 ,f 1 and 6b 2 ), str. radiatum (p = 0.036) of the CA3 region (Figs 5b 1 ,f 1 and 6b 3 ) and a significant decrease (p = 0.03) in the DG str. moleculare (Figs 5b 1 ,f 1 and 6b 4 ).
We found a significant decrease in GABA A R b3 subunit immunoreactivity in the str. oriens (p = 0.009) of the CA2 (Figs 5c 1 ,g 1 and 6c 2 ), str. granulare (p = 0.008) and str. moleculare (p = 0.008) of the DG (Figs 5c 1 ,g 1 , 6c 4 ; 7a-d).
Expression of GABA A R c2 subunit in the human hippocampus, subiculum, entorhinal cortex and superior temporal gyrus We found a significant increase in GABA A R c2 subunit expression in the str. oriens (p = 0.03) of the CA1 (Figs 5d 1 , h 1 and 6d 1 ), in the str. pyramidale (p = 0.03) of the CA3 (Figs 5d 1 ,h 1 and 6d 3 ) , str. moleculare (p = 0.03) of the DG (Figs 5d 1 ,h 1 and 6d 4 ), the subiculum (p = 0.01) (Fig. 6d 5 ) and the entorhinal cortex (p = 0.016) (Figs 5d 2 ,h 2 , 6d 6 and 7e-h) in AD cases. In all other layers of the CA1-3 there was a trend towards an increase in GABA A R c2 subunit expression approaching, although not reaching, significance in AD cases compared to controls.
Expression of the examined GABA A R subunits did not show significant correlations with tau-and beta-amyloid load or neuronal loss in any of the brain regions examined. However, a weak trend towards positive correlation was found between neuronal loss and GABA A R a1 subunit density in the subiculum (r s = 0.5; p > 0.9) and entorhinal cortex (r s = 0.32; p > 0.9); and a weak trend towards negative correlation between neuronal loss and GABA A R c2 subunit density in the subiculum (r s = À0.5; p > 0.9) and entorhinal cortex (r s = À0.63; p = 0.5).
Discussion
We report here alterations in the expression of the GABA A R subunits in the AD hippocampus, entorhinal cortex and STG. This study shows the altered brain region-and cell layerspecific expression of GABA A R a1, a2, a5, b2, b3 and c2 subunits in the AD human hippocampal tissue samples in these brain regions. The results also reveal that some subunits, however, are relatively well preserved in AD, such as the GABA A R a3 and b1 subunits (Table 4) .
GABA A R subunit expression in the normal human hippocampus, subiculum, entorhinal cortex and superior temporal gyrus The expression of the GABA A R subunits has been examined in previous studies in the rodent (Wisden et al. 1992; Fritschy and Mohler 1995; Pirker et al. 2000; Heldt and Ressler 2007) and human hippocampus (Loup et al. 2000 (Loup et al. , 2006 Pirker et al. 2003; Stefanits et al. 2018) . The GABA A R a1, a2, a3, a5, b1, b2, b3 and c2 subunits are expressed in all brain regions examined in this study but they display a spatial distribution specific for each subunit. Within the CA1 region, the a3, b3 and c2 subunit immunoreactivity was the highest in agreement with previous findings (Loup et al. 2000; Pirker et al. 2003) . The a1, a2 and a5 subunits are also expressed but at slightly lower levels, whereas the b1 and b2 subunits displayed even weaker immunoreactivity throughout all regions of the Fig. 2 (a-h) Gamma-aminobutyric acid type A receptor a1, a2, a3 and a5 subunit expression in the hippocampus, subiculum and entorhinal cortex in Alzheimer's disease and control cases. Scale bars, 1000 lm a1-h1; 200 lm a2-h2. hippocampus subiculum, entorhinal cortex. In the STG, the a1, a5, b1 and c2 subunits displayed the strongest immunoreactivity with both neuropil and somatic labelling. In agreement with previous studies, in the human DG and CA1 we found a somatic and neuropil a1, a2 and a3 subunit labelling pattern (Loup et al. 2000; Stefanits et al. 2018) , which contrasted with the lack of a3 subunit immunoreactivity in pyramidal cells of the rat CA1 region and DG granule cells (Fritschy and Mohler 1995; Pirker et al. 2000) . For the a1 and a2 subunits the rat data are controversial, one study showed a1 immunoreactivity in pyramidal cells of the rat CA region and DG granule cells (Pirker et al. 2000) while another did not observe any staining (Fritschy and Mohler 1995) ; the same studies reported opposing results, absence (Pirker et al. 2000) and presence (Fritschy and Mohler 1995) of the a2 subunit in these cells. The week expression found in our study of a1 and a3 subunits in Fig. 4 (a-p) Photomicrographs of representative regions showing gamma-aminobutyric acid type A receptor a1, a2 and a5 subunit expression (red) and a1, a2 and a5 overlayed with NeuN (green) immunoreactivity for representative Alzheimer's disease (AD) and control cases. The figure shows a significant increase in a1 subunit expression all three layers of the CA3 region (a-d) and in the stratum (str.) granulare and hilus of the dentate gyrus (DG) (e-h) in AD cases compared to controls. AD cases show increased a2 subunit expression in the str. oriens and str. radiatum of the CA2 region (i-) and increased a5 subunit expression in the str. pyramidale and str. oriens of the CA1 region (m-p) compared to controls. Scale bars, 25 lm (a-l), 50 lm (m-p).
CA3 and CA4 is consistent with both human (Fritschy and Mohler 1995; Loup et al. 2000; Pirker et al. 2003; Stefanits et al. 2018) and rodent data (Wisden et al. 1992; Fritschy and Mohler 1995; Pirker et al. 2000; Heldt and Ressler 2007) . The a5 subunit containing GABA A Rs are highly expressed in the hippocampus. In agreement with previous data we found that they are mostly located on pyramidal cell bodies and covering the dendritic fields of the CA1 hippocampal layer (Brunig et al. 2002; Crestani et al. 2002) . The a5 subunit also showed a strong neuropil and somatic immunoreactivity in the human entorhinal cortex, whereas in the rats a relatively weak diffuse neuropil labelling has been reported (Fritschy and Mohler 1995) . The b1 and b2 subunits showed weak expression on DG granule cells, pyramidal cells and neuropil labelling in the CA regions and subiculum. A similar b1 staining pattern has been reported in rats but the b2 subunit was not present on the rat granule cells and showed a stronger labelling within the CA regions compared to our human study (Pirker et al. 2000) . A previous study reported the b2 subunit was weakly expressed throughout the human hippocampus in agreement with our results but the DG granule and pyramidal cells and neuropil labelling in the CA2 and CA3 regions that we observed were not present (Stefanits et al. 2018) .
Another study, using an antibody that recognizes both the b2 and b3 subunits, revealed a moderate to strong expression in the DG and CA regions in the rat (Fritschy and Mohler 1995) . The same antibody seems to show the strongest labelling in the human DG molecular layer and CA1 region, moderate labelling in CA2 and CA3 and hilus (Loup et al. 2000) . In contrast, we observed a relatively strong b3 staining intensity in these regions in agreement with the rat
(d1) (d2) (h1) (h2) Fig. 5 (a-h) Gamma-aminobutyric acid type A receptor b1, b2, b3 and c2 subunit expression in the hippocampus, subiculum and entorhinal cortex in Alzheimer's disease and control cases. Scale bars, 1000 lm a1-h1; 200 lm a2-h2. study. We also found an even higher labelling in the subiculum, entorhinal cortex and STG. Strong b3 subunit immunoreactivity was also reported in the DG, CA1, CA2 and CA3 regions; and a moderate b2 expression in the DG and CA1 in mice and a strong b2 DG labelling in another rat study (Wisden et al. 1992; Heldt and Ressler 2007) . Previous studies found that endothelial cells express b2 subunits (Pirker et al. 2003; Stefanits et al. 2018 ). In agreement with these studies, we also observed endothelial b2 expression, in addition to a similar endothelial b1 and b3 subunit labelling. In the subiculum, the a1, a5, b3 and c2 subunit immunoreactivity was the highest with a diffuse staining pattern in agreement with the rat data (Fritschy and Mohler 1995; Pirker et al. 2000) but in contrast with a mouse (Wisden et al. 1992) and a human study. In the mouse subiculum the a2 subunit mRNA showed the strongest expression followed by a1, a3 and b3 subunits (Wisden et al. 1992) . In a recent human study, the a3 subunit seems to show the highest expression, while the c2 subunit immunoreactivity is almost absent in the subiculum but also in all hippocampal regions (Stefanits et al. 2018 ). This discrepancy is most likely because of technical issues as the antibody used by Stefanits and colleagues in previous studies (Zimprich et al. 1991; Pirker et al. 2000) provided a stronger immunoreactivity and a staining pattern similar to that we, and Fig. 7 (a-h) Photomicrographs of representative regions showing gammaaminobutyric acid type A receptor b3 and c2 subunit expression (red) and b3, c2 overlayed with NeuN (green) immunoreactivity for representative Alzheimer's disease (AD) and control cases. The figure shows a significant decrease in b3 subunit expression in the stratum (str.) granulare and str. moleculare of the dentate gyrus (DG) (a-d) in AD cases compared to controls. AD cases show increased c2 subunit expression in the layer V of the entorhinal cortex compared to controls (e-h). Immunostaining intensity of neuronal cell bodies (arrows) is comparable between the control and AD cases (e-h) but AD cases (g and h) show stronger labelling in the neuropil compared to controls (e and f). Scale bars, 25 lm (a-h). AD, Alzheimer's disease; DG, dentate gyrus; GABA, gamma-aminobutyric acid; GABA A R, GABA type A receptor; STG, superior temporal gyrus. increase p < 0.05, increase p < 0.01, decrease p < 0.05, decrease p < 0.01 of GABA A R subunit density in AD cases compared to controls. others observed in the human hippocampus (Loup et al. 2000; Pirker et al. 2003) . A strong c2 subunit expression was detected on granule cells, pyramidal cells and neuropil in the DG and all hippocampal sub regions in both mice (Heldt and Ressler 2007) and rats (Wisden et al. 1992; Fritschy and Mohler 1995) . In the STG, the a1, a5, b1 and c2 subunits displayed the strongest immunoreactivity with both neuropil and somatic labelling.
Altered GABA A R subunit expression in the Alzheimer's disease hippocampus, subiculum, entorhinal cortex and superior temporal gyrus and functional implications Despite the marked loss of hippocampal neurons in the latestage disease some studies demonstrated a good preservation of some of the GABA A R subunits, including the b1,2/3 subunits at the protein level (Mizukami et al. 1997 (Mizukami et al. , 1998a Armstrong et al. 2003; Rissman et al. 2003) . We found that besides the GABA A R b1 the a3 subunits are also well preserved in the AD hippocampus, entorhinal cortex and STG.
Other studies have shown marked changes in GABA A R subunits in AD (Rissman et al. 2007; Iwakiri et al. 2009 ). However, which GABA A Rs subunits exhibit most change remains controversial and there is a lack of brain subregionand cell layer-specific data. Importantly, the changes we observed in GABA A R subunit expression are brain regionand layer-specific alterations in AD. Several studies using polymerase chain reaction or western blotting techniques to examine the GABA A R subunit expression did not provide detailed and in depth results related to hippocampal region or layers, mainly because of technical limitations or study design as generally the entire hippocampus or temporal cortex was sampled. A number of reports using radiolabelled ligands and peroxidase-based immunohistochemistry demonstrated relatively inconsistent results in the hippocampus or did not provide quantitative data (Reisine et al. 1978; Cross et al. 1984; Chu et al. 1987; Greenamyre et al. 1987; Shimohama et al. 1988; Jansen et al. 1990; Penney et al. 1990; Mizukami et al. 1998b; Iwakiri et al. 2009 ). Few studies found decreased GABA A R binding sites in the str. pyramidale of CA1 and subiculum (Chu et al. 1987; Penney et al. 1990 ) and other hippocampal regions (Shimohama et al. 1988) , but others reported no significant changes (Reisine et al. 1978; Cross et al. 1984; Greenamyre et al. 1987; Jansen et al. 1990) . We have used fluorescent labelling combined with confocal laser-scanning microscopy and semi-high-throughput imaging to identify in more depth specific cortical and hippocampal regions and cell layers as also used in our previous experiments which are more suitable for receptor density quantification and provide results with more sensitivity and less variability (Sousa et al. 2014; Fuhrer et al. 2017) .
Some reports show that the a1, a5 and b3 subunits display a high degree of vulnerability in the AD brain (Mizukami et al. 1998a,b; Rissman et al. 2003 Rissman et al. , 2004 . In agreement with these findings we also observed a significant reduction in these subunits in several regions and layers of the hippocampus. a1 density decreased in the str. radiatum of the CA1 region and in the str. oriens of the CA1 and str. granulare and moleculare of the DG region and subiculum. However, a1 is significantly up-regulated in all three layers of the CA3 region and in the str. granulare and hilus of the DG. It is apparent that regions with the most significant cell loss, like the CA1 (West et al. 1994) and entorhinal cortex (Gomez-Isla et al. 1996) , exhibit the most severe decrease in a1 subunit expression but interestingly no alterations are observed in the STG with a less severe but still significant cell loss (West et al. 1994; Gomez-Isla et al. 1996 Fuhrer et al. 2017 ). Rissman and colleagues reported a decreased a1 subunit expression in the human AD hippocampus at the mRNA level but at protein level, using western blotting, they did not observe significant changes (Rissman et al. , 2004 . In global a1 subunit knockout mice, the a2 ad a3 subunits are up-regulated (Kralic et al. 2002 (Kralic et al. , 2006 and the same compensatory up-regulation has been observed in the frontal and parietal cortex of forebrainspecific a1 subunit knock-out mice (Zeller et al. 2008) . The loss of a1 subunit is paralleled by a decrease in b2 and c2 subunits (Kralic et al. 2006; Ogris et al. 2006) . Interestingly, in the AD CA3 region the up-regulation of the a1 subunit is paralleled by an increased b2 and c2 subunit expression, which suggests that the well-established a1b2c2 subunit containing benzodiazepine sensitive receptor is up-regulated in CA3. The above discussed findings indicate, that these changes are not simply compensatory alterations but reflect the reorganization of defined neuronal circuits and are critical to produce a stable neuronal network (Schneider Gasser et al. 2007 ), and we provide evidence for a similar remodelling that might occur in the AD brain.
GABA A Rs mediate two distinct forms of inhibition, phasic and tonic. Phasic inhibition is mediated by synaptic GABA A Rs mostly assembled by a1, a2, a3, either b and a c2 subunit. Tonic inhibition is mediated by peri-or extrasynaptic high affinity GABA A Rs mostly assembled by a5, a4, either b and a d subunit; low concentrations of ambient GABA can persistently activate these subtypes of GABA A R to generate a tonic conductance (Farrant and Nusser 2005; Glykys and Mody 2006) . The preferential expression of a5 subunit within the hippocampus might indicate that this particular receptor subtype is associated with hippocampal functions, such as aspects of learning and memory. Indeed, several studies using pharmacological agents and genetic manipulations have confirmed that the a5 subunit plays a role in hippocampus-dependent learning (Collinson et al. 2002; Crestani et al. 2002; Chambers et al. 2004; Yee et al. 2004; Dawson et al. 2006; Gerdjikov et al. 2008) , in generating gamma oscillations and controlling network excitability within the hippocampus (Towers et al. 2004; Scimemi et al. 2005; Glykys and Mody 2006) . Some studies have reported a moderately decreased a5 subunit expression at the mRNA and protein level in the CA1-3 (Rissman et al. , 2004 and moderate decrease in a5 subunit ligand binding (Howell et al. 2000) in the AD hippocampus. We also found that the a5 subunits are well preserved in the AD hippocampus, subiculum, entorhinal cortex and STG but detected a significant increase in the expression in the str. pyramidale, str. oriens of the CA1 regions and the subiculum. In these brain regions, levels of the potential partner subunits, b2 and c2 were unaltered or also up-regulated. Thus, a therapeutic approach targeting preferentially the a5 subunit containing GABA A Rs may be a promising strategy to restore inhibition in the hippocampus but more research is needed to understand how GABAergic function is altered in the human AD brain. GABA A R a5 subunit knockout or point mutant mice have enhanced cognitive performance (Collinson et al. 2002; Crestani et al. 2002) . Furthermore, the administration of inverse agonists of a5 subunit containing GABA A Rs enhances cognition in rodents (Dawson et al. 2006; Martin et al. 2009 ), nonhuman primates and humans (Atack 2010) . In contrast, increased cell surface expression of the a5 subunit in the hippocampus is associated with memory loss (Wang et al. 2012) . These findings suggest that up-regulation of the a5 subunit observed within the CA1 hippocampal region might lead to cognitive deficits in AD. The up-regulation maybe compensatory for the altered GABAergic tone a mechanism to enhance tonic inhibition. In the 5xFAD mouse AD model, functional and behavioural analyses demonstrated that increased tonic inhibition in the DG suppresses long-term potentiation (LTP) and results in memory deficit. Wu and colleagues suggest that in the DG of AD brains, excitotoxic/ inflammatory stimulation, possibly originated from betaamyloid deposits, will stimulate reactive astrocytes to accumulate glutamate and convert it into GABA, than release and increase ambient GABA concentration. The a5 subunit containing GABA A Rs in AD dentate granule cells are up-regulated to further enhance tonic inhibition and the GAT-3 transporter is up-regulated as well to mediate GABA release (Wu et al. 2014) . While this seems as a good working model, our results question the validity of the model and the hypothesis as in the human AD DG granule cell layer we did not find up-regulation of the a5 subunit and the GAT-3 transporter (Fuhrer et al. 2017) . However, in control cases, the a5 and b2 subunits displayed immunoreactivity in the subgranular layer of DG, that represents the basal dendrites of the granule cells and a region in the hippocampus where adult neurogenesis occurs (Pino et al. 2017) , and interestingly this labelling was absent in AD cases. AD patients exhibit a decrease in cell proliferation and changes in neurogenesis in the subgranular zone, however, the mechanism and significance of these changes are not fully understood (Lazarov and Marr 2010; Choi et al. 2016) . GABA and components of the GABA signalling are key regulators of embryonic and adult neurogenesis (Ge et al. 2006; Lazarov and Marr 2010) and the GABA A R b2 and a5 subunits might be implicated in this process. The GABA A R a5 containing receptors mediate tonic inhibition. Before receiving any synaptic innervations, newborn granule cells in DG of the adult hippocampus are tonically activated by ambient GABA. These neurons need to sense neuronal network activities through local ambient GABA levels (Ge et al. 2006 ) and altered GABA signalling might cause dysfunction of this tonic activation and the integration of new neurons in the adult brain.
We report decreased GABA A R b3 subunit density in the str. oriens of the CA1 region, str. granulare and str. moleculare of the DG and subiculum. While Mizukami and colleagues show that b3 subunits expression decreased at the mRNA level, they did not report significant decrease at protein level, but importantly the antisera used for this study recognizes both b2/3 (Mizukami et al. 1997) . Our results also show a significant increase in the b2 subunit expression in the str. oriens and str. radiatum of the CA2 and str. radiatum of the CA3 regions, similar trends are reported by Mizukami and colleagues using in situ hybridization but not reaching significance owing to the high variability between the cases examined (Mizukami et al. 1998a) , and this can explain the discrepancy in their findings. Also their study did not include a healthy age-matched control group, and the differences between this control group and the severe AD group might be more striking than between the mild, moderate and severe AD groups (Mizukami et al. 1998a ). This study also shows a trend towards decrease in the b2 and a significant decrease in the b3 subunit expression in the DG in agreement with our findings, showing a significant decrease in the str. moleculare, a trend towards decrease in the str. granulare for the b2 subunit, and for the b3 subunit in the str. granulare and hilus.
Iwakiri and colleagues found that the GABA A R c1/3 subunits exhibited more intense immunoreactivity in several end-stage AD subjects compared to the mild and moderate cases and c2 subunit expression was preserved in the AD hippocampus (Iwakiri et al. 2009 ). However, quantitative data were not obtained. Interestingly, neurons immunoreactive to c subunits do not contain neurofibrillary tangles (Iwakiri et al. 2009 ). We observed that the c2 subunit labelling was slightly increased or showed a trend towards increase in all regions of the hippocampus and subiculum in the AD group compared to controls. These findings suggest that up-regulation or preservation of the c subunit expression may protect neurons against neurofibrillary pathology in AD or the loss of these neurons precedes neurofibrillary degeneration. In regions like the CA1 (West et al. 1994) , entorhinal cortex (Gomez-Isla et al. 1996) and STG (GomezIsla et al. 1997) with the most severe cell loss and increased c2 subunit labelling it is proposed that the death of the pyramidal neurons precedes the neurofibrillary pathology and there is an up-regulation of c subunits on more resistant neurons and neuronal processes, including especially the GABAergic neurons (Reinikainen et al. 1988) . Limon et al. (2012) , found a significant reduction in a1,2,5, b2,3 and c2 expression within the Alzheimer's human temporal cortex at mRNA level but subregion-specific changes were not examined. Our results are supported by these findings as we observed a significant reduction in GABA A R a2 and a5 subunit expression in the STG and trend towards decrease for the b2 and c2 subunit expression. There are no previous immunohistochemical studies examining the expression of the GABA A Rs subunits in the entorhinal cortex in AD. However, we and some other studies using radiolabelled ligands found decreased GABA A R binding sites in the entorhinal (Jansen et al. 1990) , parahippocampal (Greenamyre et al. 1987 ) and temporal cortex (Owen et al. 1983; Cross et al. 1984; Shimohama et al. 1988; Carlson et al. 1993) . In this study we show that most subunits are well preserved in this region except the a1 expression that significantly decreased and the c2 subunit exhibited increased expression.
GABA A R subunit expression changes have been detected in other disease conditions, for instance in epilepsy and Huntington's disease. In Huntington's disease the primary neurons that degenerate are the GABAergic medium spiny projection neurons of the striatum, which causes a marked up-regulation of GABA A R subunits a1, b2 and c2 in the postsynaptic neurons of the globus pallidus and substantia nigra. These changes might naturally slow the progression of the disease symptomatology (motor and mood) by compensating for the loss of striatal GABAergic neurons . In AD cases, we see increased a 1 , b 2 and c 2 subunit immunostaining density in several brain regions examined, with the CA3 and DG being most affected. A similar compensatory mechanism owing to the significant neuronal loss found in the AD brain might be contributing to the upregulation we found but as discussed below this does not underlie all the changes seen and is a region-specific phenomenon. The increased a 1 subunit labelling is very prominent on processes of interneurons and possibly on Mossy fibres that project to the polymorphic layer of the dentate gyrus and show AD-specific alterations (Kiktenko et al. 1995; Wilke et al. 2014) . In the hippocampus of the hAPP FAD AD mouse model axonal sprouting of GABAergic interneurons with an increased neuropeptide Y expression and increased inhibitory synaptic activity are compensatory changes in response to increased excitability and suggests an imbalance between excitation and inhibition (Vezzani et al. 1999; Palop et al. 2007) . A subset of these mice also exhibited frequent epileptiform discharges and intermittent non-convulsive seizures. A similar GABAergic sprouting with aberrant increase in neuronal activity has also been found in animal models of chronic epilepsy (Vezzani et al. 1999) . The sprouting of Mossy fiber axons in dentate gyrus and CA3 has also been described in epilepsy and might be present in the AD hippocampus as patients with this condition are at increased risk for developing seizures (Loup et al. 2000; Buckmaster 2012; Friedman et al. 2012) . However, the cause/ effect relationship between the sprouting and these disease conditions is unclear and controversial but it has been shown that the extent of Mossy fibre sprouting correlates with hilar neuronal loss in patients with mesial temporal lobe epilepsy and in animal models the sprouting creates a positive feedback circuit among granule cells leading to an aberrant, recurrent excitatory circuit (Buckmaster 2012) . Interestingly, increasing a1 expression by viral gene transfer in DG is effective to inhibit development of acquired epilepsy in rats, suggesting that the increase in a1 expression observed in the AD DG might be a compensatory mechanism to prevent seizures. Furthermore, the loss of GABAergic terminals has been shown to underlie the reduced neurotransmitter release and abnormal expression of GABA A R subunits in postsynaptic neurons, on DG granule cell dendrites, and contribute to neuronal hyperexcitability in a mouse model of epilepsy (Zhang et al. 2007) . Hence, terminal atrophy described in AD (Walker et al. 1985; Hardy et al. 1987) probably also could induce altered GABA A R subunit expression.
The physiological consequences of altered GABA A R subunit composition remain to be established but most probably they are related to cognitive and behavioural changes and altered pharmacological receptor properties. GABA A R subunit mutant mice are very useful tools to identify behavioural functions mediated by different GABA A R subtypes. These studies suggest that the a2b3c2 subunit combination is mediating anxiolysis (Crestani and Rudolph 2015) . The c2 knockouts die shortly after birth but the c2 +/À mice are models for anxiety characterized by harm avoidance behaviour and explicit memory bias for threat cues, leading to heightened sensitivity to negative associations (Crestani et al. 1999) . These mice are also models of behavioural despair with a depressive-like phenotype (Earnheart et al. 2007) . The b3 subunit is also essential for general anaesthesia (Jurd et al. 2003) . The GABA A Rs are the targets of the widely used drugs, benzodiazepines. They are one of the strongest anticonvulsive, sedative-hypnotic and anxiolytic compounds in clinical use. The sedative action of diazepam is mediated by GABA A Rs containing the a1 subunit Crestani and Rudolph 2015) . The a5 subunits are important for the development of tolerance to the sedative action of diazepam as revealed by mouse mutant studies (van Rijnsoever et al. 2004) . As discussed earlier, AD-related GABA A R subunit changes affecting the a5 subunit containing GABA A Rs will probably also lead to cognitive changes, influence memory formation and performance. All these data indicate that the altered expression of GABA A R a1, a2, a5, b2, b3 and c2 subunits in the AD hippocampus, entorhinal cortex and STG will have significant behavioural effects -particularly related to cognition, amnesia, anxiety, depression -as well as changes and responses to GABAergic drugs like, benzodiazepines and anaesthetics. Besides cognitive deficits various noncognitive symptoms termed behavioural and psychological symptoms of dementia (BPSD) are common in AD (Lyketsos et al. 2000) . BPSD have been observed in up to 60% to 98% of patients with dementia and include agitation, aggression, anxiety, delusions, sleep disturbances and hallucinations among other symptoms (Margallo-Lana et al. 2001; Dourado and Laks 2016) . Despite the fact that the links between increased risk of dementia and prolonged benzodiazepine usage are controversial, benzodiazepines are commonly used in clinical practice to reduce BPSD exhibited by AD patients (Conn et al. 1999; Saarelainen et al. 2017) . Importantly, these studies and our findings suggest that further research is needed to clarify how altered GABA A R subunit expression, composition and pharmacology in AD patients might change GABAergic drug responses (Govindpani et al. 2017) .
While each study design has limitations, and findings in the literature are often inconsistent, a great number of studies provide evidence that GABA A R expression and function is severely altered in AD (Govindpani et al. 2017) . However, the identification of the exact localization of altered GABA A Rs and understanding the pharmacological and physiological consequences of these changes in the AD brain is critical to identify the most suitable therapeutic targets. This research provides a detailed brain region and cell layerspecific characterization of the GABA A R subunit alterations in AD and helps to understand the underlying pathology of AD. These data highlight that although principal GABA A R subunits are reduced in certain areas/layers of the AD hippocampus, in some other areas/layers the same subunit expression might not show any changes or will increase, suggesting the need to better understand these changes to design effective AD treatments. These data also suggest that more targeted therapeutic strategies might be needed to restore or compensate these changes and achieve any desired outcome. Importantly, reduction and increase in GABA A R subunits were detected in regions of the hippocampus showing significant cell loss, as well as regions with modest, if any, cell loss. These findings show that alterations in GABA A R signalling found in AD does not correlate with the neuronal loss, likely occurring prior to cell death, and could be a primary mechanism contributing to cognitive decline and not secondary to neurodegeneration. However, GABA A R subunit expression can be also increased on the neurons that are resistant to AD pathology, specifically on interneurons (Reinikainen et al. 1988) , because some subpopulations of these cells express GABA A Rs receptors at high level (Houser et al. 1988; Mohler et al. 1996; Loup et al. 2000; Waldvogel et al. 2008) . The changes in GABA A R subunit composition in AD (Limon et al. 2012) affects GABA binding and drug responses in a brain region-specific manner but the consequences of these changes on cognitive impairment and AD pathology are yet to be determined. What makes it challenging to address these questions is the fact that none of the AD animal models are capable of accurately modelling the complex molecular, cellular, pathological and behavioural changes inherent in the human disease. Furthermore, besides the GABA A R subunit expression changes the alterations in GABA levels, GABA transporters and GABA current also have a significant impact on neuronal function and progression of the disease and have to be considered when targeting the GABAergic system in AD. Indeed, many GABAergic drugs have been studied in relation to AD, some of them targeting the impaired excitatory/inhibitory balance while others ameliorating the neurotoxic effect of beta-amyloid (Atack 2010; Drott et al. 2010; Vellas et al. 2011; Solas et al. 2015; Li et al. 2016; Govindpani et al. 2017) .
In conclusion, these data demonstrate that GABA A R subunits show unique responses to AD pathology, and they are differentially affected within the cell layers and regions of the hippocampus, subiculum, entorhinal cortex and STG. The next step will be elucidating the underlying cause of these GABA A R subunit changes and the functional consequences that will enhance our understanding of AD pathology and open new therapeutic avenues for treatment with brain region specific and more defined molecular targets compared to already tested GABAergic therapeutic approaches. These findings will better inform clinical trials utilizing GABAergic drugs as neuroprotective and diseasemodifying agents.
